



Sharing Progress  
in Cancer Care

SPCC Educational Project on  
**Interstitial Lung Disease (ILD) as a  
Cancer Treatment Induced  
Adverse Event**



Sharing Progress  
in Cancer Care

## WEBINAR 1

**Title:** “Breast cancer drugs and Interstitial Lung Disease (ILD): more news”

**Date:** Wednesday 30 November 2022 at 18:00 CET

### Programme

- 18:00-18:03 Introduction
- 18:03-18:16 Interstitial lung disease (ILD) and monoclonal antibodies – **Veronique Dieras, FR**
- 18:16-18:29 Interstitial lung disease (ILD), mTOR inhibitors and CDK4/6 inhibitors: frequency and practical management - **Alfredo Addeo, CH**
- 18:29-18:42 Interstitial lung disease (ILD) and ADCs or T-DXd and other ADCs: realities and guidelines for management – **Giampaolo Bianchini, IT**
- 18:42-18:55 Discussion focused on daily practice and Q&A - **Chairs and Experts**
- 18:55-19:00 Take Home Messages and Closure

### Faculty

**Discussant:** Hope Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco, US

**Discussant / Expert:** Veronique Dieras, Senior Medical Oncologist at Centre Eugène-Marquis, Rennes, FR

**Expert:** Alfredo Addeo, Oncology Division, University Hospital Geneva, CH

**Expert:** Giampaolo Bianchini, Head Breast Cancer Group; Head translational and immunotherapy research group; San Rafael Scientific Institute, Milan, IT